PL2792681T3 - Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNS - Google Patents
Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNSInfo
- Publication number
- PL2792681T3 PL2792681T3 PL14154304T PL14154304T PL2792681T3 PL 2792681 T3 PL2792681 T3 PL 2792681T3 PL 14154304 T PL14154304 T PL 14154304T PL 14154304 T PL14154304 T PL 14154304T PL 2792681 T3 PL2792681 T3 PL 2792681T3
- Authority
- PL
- Poland
- Prior art keywords
- pregnane
- manufacture
- treatment
- pharmaceutical composition
- cns disorders
- Prior art date
Links
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 title 1
- -1 androstane steroids Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86065806P | 2006-11-21 | 2006-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2792681T3 true PL2792681T3 (pl) | 2017-06-30 |
Family
ID=39429970
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14154304T PL2792681T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNS |
| PL13198584T PL2711371T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| PL07835459T PL2097437T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13198584T PL2711371T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| PL07835459T PL2097437T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN |
Country Status (16)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664126C (en) | 2006-11-21 | 2014-04-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| AU2011205821B2 (en) | 2010-01-14 | 2013-07-25 | Relmada Therapeutics, Inc. | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| WO2011138460A1 (en) * | 2010-05-07 | 2011-11-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Progesterone receptor antagonists and uses thereof |
| EP4245369A3 (en) | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SI2925770T1 (sl) * | 2012-11-28 | 2017-07-31 | Institut National De La Sante Et De La Recherche Medicale(Inserm) | 3-(4'-substituirani)-benzil-eter derivati pregnenolona |
| SI3461834T1 (sl) | 2013-03-13 | 2021-11-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi |
| SI3099306T1 (sl) * | 2014-01-29 | 2019-03-29 | Umecrine Cognition Ab | Steroidna spojina za uporabo v zdravljenju hepatične encefalopatije |
| EP4306114A1 (en) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HRP20200840T1 (hr) * | 2014-11-27 | 2020-11-13 | Sage Therapeutics, Inc. | Pripravci i postupci za liječenje poremećaja cns-a |
| TWI748936B (zh) * | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| RU2021100377A (ru) | 2015-07-06 | 2021-05-18 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
| CA3019146C (en) | 2016-04-01 | 2024-03-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| IL297804A (en) | 2016-10-18 | 2022-12-01 | Sage Therapeutics Inc | Oxysterols and methods of using them |
| IL293231B1 (en) | 2016-10-18 | 2025-06-01 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| EP3579843A4 (en) | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN MEDICAL TREATMENT |
| WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| WO2019102040A1 (en) | 2017-11-27 | 2019-05-31 | Umecrine Cognition Ab | PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME |
| RU2020130861A (ru) | 2018-04-05 | 2022-05-05 | Асарина Фарма Апс | Антагонисты гамка для применения в лечении расстройств отмены психоактивного вещества |
| CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
| EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
| EP4430057A1 (en) | 2021-11-10 | 2024-09-18 | Umecrine AB | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4389129A1 (en) | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1463755A (fr) | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
| US3152121A (en) * | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
| CH491889A (de) * | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
| JP4008024B2 (ja) * | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| PT752860E (pt) * | 1994-02-14 | 2000-12-29 | Euro Celtique Sa | Androstanos e pregnanos para modulacao alosterica do receptor de gaba |
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| CA2223996A1 (en) | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| EP1063999B1 (en) | 1998-03-11 | 2005-10-26 | Torbjörn Backström | Epiallopregnanolone in the treatment of cns disorders |
| WO1999052532A1 (en) | 1998-04-14 | 1999-10-21 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| FR2831441B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
| EP1310258A1 (en) * | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| EP1812009B1 (en) * | 2004-11-18 | 2013-05-15 | Umecrine AB | Gaba-steroid antagonists and their use for the treatment of cns disorders |
| CA2664126C (en) | 2006-11-21 | 2014-04-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| WO2011138460A1 (en) | 2010-05-07 | 2011-11-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en active Application Filing
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
-
2012
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja not_active Expired - Fee Related
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2097437T3 (pl) | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN | |
| SI1919450T1 (sl) | Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj | |
| SI2027140T1 (sl) | Industrijski proces za sintezo 17 alfa -acetoksi-11 beta -(4-(n,n- dimetil-amino)-fenil)-19-norpregna-4,9-dien-3,20-diona in novi intermediati postopka | |
| EP2099449A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE | |
| PL2102169T3 (pl) | Amidowe pochodne indazolilu do leczenia zaburzeń pośredniczonych receptorem glukokortykoidowym | |
| EP1986639A4 (en) | PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES | |
| IL213959A0 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
| PL1744760T3 (pl) | Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami | |
| EP2318005A4 (en) | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| EP2044108A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION | |
| IL190522A (en) | A medicinal product containing hydrocarbon testosterone gel and use of testosterone to make the preparation | |
| EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| PL2121025T3 (pl) | Sposoby i kompozycje dla dostarczania czynnika terapeutycznego | |
| EP2004216A4 (en) | AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF | |
| IL201632A0 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| EP2056857A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION | |
| PL2004668T3 (pl) | Pochodne aminowe androstanów i androstenów jako leki do leczenia zaburzeń sercowo-naczyniowych | |
| IL200044A (en) | Tricyclic compounds as modulators of a glucocorticoid receptor and their use in the preparation of drugs for the treatment of diseases | |
| ZA200609685B (en) | Pharmaceutical compositions for acute glucocorticoid therapy | |
| IL204957A (en) | Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten | |
| IL202205A (en) | Process for the preparation of steroids converted at position 17α by 3-hydroxypropyl and at position 17ß - by hydroxy from the corresponding 14-oxo history and intermediates obtained in this process | |
| AU2006906505A0 (en) | Agent for the treatment of hormone-dependent disorders and uses thereof | |
| HU0600815D0 (en) | Pharmaceutical composition for the treatment of obstructive and inflammatory disorders of the respiratory tract | |
| AU2007906680A0 (en) | Methods and compositions for the treatment of phosphatase-related disorders |